Our business
The Abacus Medicine Group supplies prescription medicine to thousands of customers across the world.
Every day, our employees work to provide better access to medicine and thereby better healthcare for all. Our core business is known as parallel import of medicine, but we are also well-established within other pharmaceutical and healthcare services such as clinical trial solutions, wholesaler and direct-to-patient services.
We supply medicine to more than 30 countries worldwide. Our main markets are in Europe with a growing presence in Asia Pacific and the US. We operate in a number of locations including our headquarters in Denmark and sales offices in Germany, Austria, the Netherlands, Hong Kong and the headquarters for Abacus Medicine Pharma Services in the United Kingdom. Besides our sales offices, we have production and warehouse facilities in both Hungary and the Netherlands.
The Group operates as four brands: Abacus Medicine, Pluripharm, Abacus Medicine Pharma Services and Originalis. Each brand has a distinct core capability that is supported by multiple, cross-unit competencies including logistics, trading data analytics and a strong, pan-european sourcing network.
Our business units
Abacus Medicine
Abacus Medicine is the original company of the Abacus Medicine Group, founded in 2004 by CEO Flemming Wagner and his father John Wagner (1932-2018)
The Abacus Medicine business is firmly established among the market leaders in the European parallel distribution industry. Abacus Medicine differentiates itself through an ambitious, multi-market strategy.
At the heart of the Abacus Medicine parallel distribution business model lies arbitrage trading based on price differences across Europe. In the EU, the price of prescription medicine varies significantly from one country to another.
Abacus Medicine creates value in the market and for our customers by importing medicine from EU countries with lower prices to EU countries with higher prices to sell at a lower price than the original manufacturer.
Supplying medicine at lower prices not only benefits our customers but also society at large. Abacus Medicine creates competition in a market characterized by rising healthcare costs to the benefit of patients and public budgets alike. Patients gain access to life-critical medicines at more affordable prices, and public spending on medicine is significantly reduced.
Pluripharm
Pluripharm was established in 1984 and is one of the four leading pharmaceutical wholesalers in the Netherlands. Pluripharm joined the Abacus Medicine Group in 2020.
Over the past 40 years, Pluripharm has grown into an independent, fully stocked pharmaceutical wholesaler with a complete service portfolio delivering to independent community pharmacies, as well as outpatient and hospital pharmacies throughout the Netherlands. The company specializes in patient-specific care logistics and support, offering data-driven services designed to enhance high-quality pharmaceutical care and efficient practice management.
Pluripharm’s certified online pharmacy, Thuisapotheek, specializes in fast and reliable home delivery of prescription medicines throughout the Netherlands. It also offers, in collaboration with healthcare professionals, a range of special programs such as Stop Smoking and Controlled Weight Loss.
Abacus Medicine Pharma Services
Abacus Medicine Pharma Services (AMPS) is the pharma services division of the Abacus Medicine Group and launched in 2014. We provide bespoke, end-to-end commercialisation solutions for global innovators who want to successfully launch their products in the European Union and United Kingdom.
The combination of AMPS’ industry experience with the market-leading operational capabilities of the Group provides our clients with a trusted framework for launching their innovative assets and achieving their commercial objectives.
Originalis
Originalis is a parallel distributor of medicine just like Abacus Medicine.
The Originalis brand was first introduced in the Netherlands and has since been introduced in both Ireland and Germany to provide customers with more options to choose from and thereby more options for significant savings.
Financial Results
Since the company was founded in 2004, an entrepreneurial spirit and a determination to see possibilities instead of limitations have been the main drivers behind the impressive development of the Abacus Medicine Group.
We have achieved significant organic growth in each year of our existence. But while consistent in delivering results, the company has undergone rapid development over the years.
We have adapted to market changes and found new business in new markets, new products, and new services.
Annual Report 2024
Numbers, earnings and more. How did we progress and what are our plans?
Previous Annual Reports
